NFA
MRTX

Nationwide Fund Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Nationwide Fund Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,245
Closed -$38K – 3283
2017
Q1 		$38K Hold
7,245
– – ﹤0.01% 3027
2016
Q4 		$34K Hold
7,245
– – ﹤0.01% 3050
2016
Q3 		$48K Hold
7,245
– – ﹤0.01% 3052
2016
Q2 		$40K Hold
7,245
– – ﹤0.01% 3106
2016
Q1 		$155K Buy
7,245
+11
+0.2% +$246 ﹤0.01% 2642
2015
Q4 		$229K Buy
7,234
+591
+9% +$20.9K ﹤0.01% 2480
2015
Q3 		$229K Buy
6,643
+220
+3% +$6.65K ﹤0.01% 2493
2015
Q2 		$202K Buy
6,423
+967
+18% +$28.5K ﹤0.01% 2705
2015
Q1 		$160K Buy
5,456
+73
+1% +$1.71K ﹤0.01% 2802
2014
Q4 		$100K Buy
5,383
+118
+2% +$1.99K ﹤0.01% 2906
2014
Q3 		$92K Sell
5,265
-5
-0.1% -$93 ﹤0.01% 3013
2014
Q2 		$105K Buy
+5,270
New +$102K ﹤0.01% 3012

Other funds holding MRTX

AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Nationwide Fund Advisors's MRTX Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2017, closing a stake of 7,245 shares — an estimated $38K sold.

Nationwide Fund Advisors first reported a position in MRTX in Q2 2014 and held it in 12 quarters. The position peaked at $229K in Q4 2015. 51 funds tracked by Wall St. Rank hold MRTX as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 7,245 Mirati Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $38K.
  • Nationwide Fund Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and held it in 12 quarters.
  • Nationwide Fund Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $229K in Q4 2015.
  • 51 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.